Reaction
Pituitary Tumour reporting signals
As of the last recalculation, Pituitary Tumour appears in 1,478 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 60.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 121 | 60.5 | 60.7 |
| Lanreotide Acetate | 15 | 27.2 | 27.3 |
| Somatropin | 124 | 25.9 | 25.9 |
| Dalteparin Sodium | 18 | 24.2 | 24.3 |
| Ado-Trastuzumab Emtansine | 13 | 21.9 | 21.9 |
| Paliperidone Palmitate | 32 | 14.3 | 14.3 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 6 | 9.8 | 9.9 |
| Pertuzumab | 18 | 9.4 | 9.4 |
| Paliperidone | 14 | 8.5 | 8.5 |
| Asfotase Alfa | 6 | 8.5 | 8.5 |
| Ziprasidone Mesylate | 7 | 6.9 | 6.9 |
| Diroximel Fumarate | 3 | 3.6 | 3.6 |